Trial Profile
A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2015
Price :
$35
*
At a glance
- Drugs Adefovir (Primary) ; Entecavir (Primary) ; Lamivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 12 Dec 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 04 Dec 2009 Planned initiation date changed from Nov 2009 to Dec 2009 as reported by ClinicalTrials.gov.
- 28 Oct 2009 Planned initiation date changed from 1 Dec 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.